Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel

Shuquan Rao; Yao Yao; Wenxuan Huo; Yang Cao; Lihua E. Budde

doi:10.1016/j.xinn.2024.100619

The Innovation > 2024 Vol. 5 > No. 3

Next Article Previous Article

News & Buzz Open Access

Cite PDF

Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel

1.
State Key Laboratory of Experimental Hematology, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China
2.
Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing 100044, China
3.
Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China
4.
Department of Hematology & Cancer Biology Research Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
5.
Department of Hematology & Hematopoietic Stem Cell Transplantation, City of Hope National Medical Center, Duarte, CA 91010, USA

More Information

⁶These authors contributed equally
Corresponding authors: raoshuquan@ihcams.ac.cn (S.R); ebudde@coh.org (L.E.B.)
Received Date: 29 January 2024

Accepted Date: 27 March 2024

Published Online: 30 March 2024

The Innovation 5(3), https://doi.org/10.1016/j.xinn.2024.100619 | Cite this article

FullText(HTML)

REFERENCES

[1]	Kato, G.J., Piel, F.B., Reid, C.D., et al. (2018). Sickle cell disease. Nat. Rev. Dis. Primers 4: 18010. https://doi.org/10.1038/nrdp.2018.10. View in Article CrossRef Google Scholar
[2]	Origa, R. (2017). β-Thalassemia. Genet. Med. 19: 609-619. https://doi.org/10.1038/gim.2016.173. View in Article CrossRef Google Scholar
[3]	Frangoul, H., Altshuler, D., Cappellini, M.D., et al. (2021). CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. N. Engl. J. Med. *384*: 252-260. https://doi.org/10.1056/NEJMoa2031054. View in Article CrossRef Google Scholar
[4]	(2023). FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease. (FDA News release). https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease. View in Article Google Scholar
[5]	(2024). CASGEVY (exagamglogene autotemcel) suspension for intravenous infusion. https://pi.vrtx.com/files/uspi_exagamglogene_autotemcel.pdf. View in Article Google Scholar

CITED BY

ABOUT THIS ARTICLE

Cite this article:

Rao S., Yao Y., Huo W., et al., (2024). Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel. The Innovation 5(3), 100619. https://doi.org/10.1016/j.xinn.2024.100619

Rao S., Yao Y., Huo W., et al., (2024). Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel. The Innovation 5(3), 100619. https://doi.org/10.1016/j.xinn.2024.100619

Welcome!

To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.

PDF

Figures(1)

Article Metrics

Article views(1041) PDF downloads(237) Cited by(0)

Relative Articles

Article Contents

ABOUT THIS ARTICLE

Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel

REFERENCES

ABOUT THIS ARTICLE

Cite this article:

Welcome!

Share

Article Metrics

Relative Articles

Catalog

{{newsColumn.name}}

Journal links

{{newsColumn.name}}

Collections

Stay connected

Revolutionizing genetic disease treatment: The case of exagamglogene autotemcel

REFERENCES

ABOUT THIS ARTICLE

Cite this article:

Welcome!

Share

Article Metrics

Relative Articles

Catalog

Export File

Citation

Format

Content

{{newsColumn.name}}

Journal links

{{newsColumn.name}}

Collections

Stay connected